Skip to main content
OTCMKTS:IRBS

IR Biosciences Stock Forecast, Price & News

$0.0002
0.00 (0.00 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
$0.09
VolumeN/A
Average Volume103,593 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta19.66
30 days | 90 days | 365 days | Advanced Chart
Receive IRBS News and Ratings via Email

Sign-up to receive the latest news and ratings for IR Biosciences and its competitors with MarketBeat's FREE daily newsletter.


About IR Biosciences

IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. The company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. It is involved in the development of Homspera, and its derivates Radilex and Viprovex, for human stem cell stimulation, immune system stimulation and anti-infective activity, vaccine adjuvancy, and wound healing. IR BioSciences Holdings, Inc. was founded in 1999 and is headquartered in Scottsdale, Arizona.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IRBS
CUSIPN/A
CIKN/A
Phone480-922-3926
Employees4
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

2007th out of 2,050 stocks

Pharmaceutical Preparations Industry

766th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











IR Biosciences (OTCMKTS:IRBS) Frequently Asked Questions

What stocks does MarketBeat like better than IR Biosciences?

Wall Street analysts have given IR Biosciences a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IR Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are IR Biosciences' key executives?

IR Biosciences' management team includes the following people:
  • Dr. Chet Leach Ph.D., D.A.B.T., Consultant

Who are some of IR Biosciences' key competitors?

What is IR Biosciences' stock symbol?

IR Biosciences trades on the OTCMKTS under the ticker symbol "IRBS."

How do I buy shares of IR Biosciences?

Shares of IRBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IR Biosciences' stock price today?

One share of IRBS stock can currently be purchased for approximately $0.00.

How many employees does IR Biosciences have?

IR Biosciences employs 4 workers across the globe.

What is IR Biosciences' official website?

The official website for IR Biosciences is www.immuneregen.com.

Where are IR Biosciences' headquarters?

IR Biosciences is headquartered at 8767 E. VIA DE VENTURA, SCOTTSDALE AZ, 85258.

How can I contact IR Biosciences?

IR Biosciences' mailing address is 8767 E. VIA DE VENTURA, SCOTTSDALE AZ, 85258. The company can be reached via phone at 480-922-3926 or via email at [email protected]


This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.